Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review
نویسندگان
چکیده
منابع مشابه
Successful Treatment with Thrombopoietin Receptor Agonist in Avoiding Splenectomy for Patients with Chronic Refractory Immune Thrombocytopenia
BACKGROUND Chronic immune thrombocytopenia (ITP) is a condition associated with significant morbidity; however the management options are often unsatisfactory with a portion of patients exhibiting a refractory-relapsing disease path despite various lines of treatment including splenectomy. As a thrombopoietin receptor agonist, eltrombopag (GlaxoSmithKline, Australia) provides a novel treatment ...
متن کاملThrombopoietin: a potential diagnostic indicator of immune thrombocytopenia in pregnancy
To evaluate whether the serum thrombopoietin levels in pregnancy-associated immune thrombocytopenia (ITP) differ from those in gestational thrombocytopenia, and reveal the possibility of thrombopoietin serving as a marker for differential diagnosis. Serum thrombopoietin concentration was determined in ITP in pregnancy (n = 35), gestational thrombocytopenia (n = 31), healthy pregnancy (n = 32), ...
متن کاملA randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.
Stimulation of platelet production by thrombopoietin-receptor agonists (TPO-RAs) is an effective second-line treatment in immune thrombocytopenia (ITP). This 28-day phase 2 study assigned subjects with ITP of ≥3 months to once-daily oral avatrombopag (2.5, 5, 10, or 20 mg), an investigational nonpeptide TPO-RA active in humans, or placebo; subjects completing randomized treatment could enroll i...
متن کاملChronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist.
Immune thrombocytopenia (ITP) is an acquired hematological disease in which the body produces antibodies against its own platelets leading to platelet destruction resulting in isolated thrombocytopenia. Childhood ITP may enter complete remission in the majority of cases within six months from diagnosis. However, 20-30% of affected children may develop chronic ITP (lasting for more than 12 month...
متن کاملWill thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
2015 Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count and increased bleeding tendency. Most children with ITP spontaneously recover. However, children with severe bleeding may require treatment. Traditional treatments such as corticosteroids or splenectomy are often associated with increased risks of infections. Currently, there is evidence that plat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutic Advances in Hematology
سال: 2021
ISSN: 2040-6207,2040-6215
DOI: 10.1177/20406207211001139